Neurenati Therapeutics
Montréal
About Neurenati Therapeutics
Neurenati Therapeutics operates as a biotechnology company developing an innovative treatment for Hirschsprung disease. Neurenati Therapeutics is pioneering a groundbreaking approach to address Hirschsprung disease (HSCR), a severe gastrointestinal (GI) birth defect marked by the absence of nerves in segments of the lower GI tract. Their cutting-edge technology introduces a novel therapy utilizing growth factors to effectively treat infants with HSCR, potentially eliminating the necessity for surgery and mitigating related risks and complications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $2.6M
- Funding stage: Seed
- Last round: Seed (Apr 2024)
- Website: neurenati.com
- Phone: (514) 825-9035
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/neurenati-therapeutics-109680 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.